Phase II study of bortezomib in patients with previously treated advanced urothelial tract transitional cell carcinoma: CALGB 90207

Por Rosenberg, J. E., Halabi, S., Sanford, B. L., Himelstein, A. L., Atkins, J. N., Hohl, R. J., Millard, F., Bajorin, D. F., Small, E. J.
Publicado no Ann Oncol (2008)

Prospective Validation of a 21-Gene Expression Assay in Breast Cancer

Por Sparano, J.A., Gray, R.J., Makower, D.F., Pritchard, K.I., Albain, K.S., Hayes, D.F., Geyer, C.E., Dees, E.C., Perez, E.A., Olson, J.A., Zujewski, J.A., Lively, T., Badve, S.S., Saphner, T.J., Wagner, L.I., Whelan, T.J., Ellis, M.J., Paik, S., Wood, W.C., Ravdin, P., Keane, M.M., Gomez Moreno, H.L., Reddy, P.S., Goggins, T.F., Mayer, I.A., Brufsky, A.M., Toppmeyer, D.L., Kaklamani, V.G., Atkins, J.N., Berenberg, J.L., Sledge, G.W.
Publicado no N Engl J Med (2015)